Biovitrum and Biogen Idec advance Factor IX product
This article was originally published in Scrip
Executive Summary
Biogen Idec and Biovitrum are to take their long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a pivotal clinical trial in haemophilia B patients.